These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 7895352

  • 1. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study.
    Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE.
    Circulation; 1995 Apr 01; 91(7):1952-8. PubMed ID: 7895352
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors.
    Katz RJ, Hsia J, Walker P, Jacobs H, Kessler C.
    Am J Cardiol; 1996 Oct 15; 78(8):876-80. PubMed ID: 8888658
    [Abstract] [Full Text] [Related]

  • 4. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.
    Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO.
    N Engl J Med; 1997 Mar 06; 336(10):683-90. PubMed ID: 9041098
    [Abstract] [Full Text] [Related]

  • 5. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women.
    Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH.
    Am J Epidemiol; 1996 Jan 15; 143(2):159-66. PubMed ID: 8546117
    [Abstract] [Full Text] [Related]

  • 6. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.
    Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE.
    Circulation; 2002 Jan 22; 105(3):304-9. PubMed ID: 11804984
    [Abstract] [Full Text] [Related]

  • 7. Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women.
    Madsen JS, Kristensen SR, Gram J, Bladbjerg EM, Henriksen FL, Gram J, Christensen K, Jespersen J.
    J Thromb Haemost; 2003 Sep 22; 1(9):1984-91. PubMed ID: 12941041
    [Abstract] [Full Text] [Related]

  • 8. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
    Lindoff C, Peterson F, Lecander I, Martinsson G, Astedt B.
    Maturitas; 1996 May 22; 24(1-2):43-50. PubMed ID: 8794433
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.
    Tofler GH, Massaro J, O'Donnell CJ, Wilson PWF, Vasan RS, Sutherland PA, Meigs JB, Levy D, D'Agostino RB.
    Thromb Res; 2016 Apr 22; 140():30-35. PubMed ID: 26896607
    [Abstract] [Full Text] [Related]

  • 11. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
    Pradhan AD, LaCroix AZ, Langer RD, Trevisan M, Lewis CE, Hsia JA, Oberman A, Kotchen JM, Ridker PM.
    Circulation; 2004 Jul 20; 110(3):292-300. PubMed ID: 15238458
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H.
    Thromb Haemost; 2001 Apr 20; 85(4):619-25. PubMed ID: 11341495
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S, Estellés A, Tormo G, Falco C, Gilabert J, España F, Cano A, Segui R, Aznar J.
    Thromb Haemost; 1999 Apr 20; 81(4):516-21. PubMed ID: 10235431
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fibrinolytic activity is similar in physically active men with and without a history of myocardial infarction.
    Fernhall B, Szymanski LM, Gorman PA, Milani J, Paup DC, Kessler CM.
    Arterioscler Thromb Vasc Biol; 1997 Jun 20; 17(6):1106-13. PubMed ID: 9194761
    [Abstract] [Full Text] [Related]

  • 19. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
    Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, Tofler GH, Grinspoon SS, Framingham Heart Study.
    J Clin Endocrinol Metab; 2001 Feb 20; 86(2):939-43. PubMed ID: 11158071
    [Abstract] [Full Text] [Related]

  • 20. Hemostatic factors and estrogen during the menopausal transition.
    Sowers MR, Matthews KA, Jannausch M, Randolph JF, McConnell D, Sutton-Tyrrell K, Little R, Lasley B, Pasternak R.
    J Clin Endocrinol Metab; 2005 Nov 20; 90(11):5942-8. PubMed ID: 16105968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.